Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

Inclusion Criteria:

• Primary or locally recurrent deep-seated extremities, girdles and/or superficialtrunk (thoracic or abdominal wall) soft tissue sarcoma

• Grade 2 or 3 tumors according to Fédération Nationale des Centres de Lutte contre leCancer (FNCLCC);

• Size of the primary tumor >5 cm at instrumental staging (CT, MRI), or locallyrecurrent of any size;

• Measurable disease based on RECIST 1.1;

• Non-metastatic disease;

Exclusion Criteria:

• Ewing sarcoma, Alveolar and embryonal rhabdomyosarcoma

• Previous treatment with eftilagimod alfa, anti-PD-1 or anti-PD-L1;

• Prior radiotherapy to tumor-involved sites;